Abstract
Compelling evidence exists to use cinacalcet as a primary therapy for the treatment of secondary HPT in patients requiring dialysis. The benefits of directly lowering PTH in combination with improving calcium-phosphorus homeostasis provide a means to better achieve the K/DOQI bone guidelines. Cinacalcet is usually well tolerated and safe to use, making it possible to treat a wide range of patients with varying levels of disease severity. The ideal course of action for this novel therapy is for nephrology nurses and renal dietitians to use a team approach in the management of secondary HPT.
MeSH terms
-
Bone and Bones / drug effects
-
Bone and Bones / metabolism
-
Cinacalcet
-
Clinical Trials, Phase III as Topic
-
Drug Administration Schedule
-
Drug Therapy, Combination
-
Evidence-Based Medicine
-
Humans
-
Hyperparathyroidism, Secondary / drug therapy*
-
Hyperparathyroidism, Secondary / etiology*
-
Hyperparathyroidism, Secondary / metabolism
-
Kidney Failure, Chronic / complications*
-
Naphthalenes / pharmacology
-
Naphthalenes / therapeutic use*
-
Parathyroid Hormone / blood
-
Patient Selection
-
Practice Guidelines as Topic
-
Renal Dialysis / adverse effects*
-
Treatment Outcome
-
Vitamin D / therapeutic use
Substances
-
Naphthalenes
-
Parathyroid Hormone
-
Vitamin D
-
Cinacalcet